(Abstract)
Introduction
High-mobility group box 1 (HMGB1) protein, a nuclear architectural chromatin-binding protein, is expressed by almost all mammalian cells, and released actively and/or passively from necrotic or damaged cells and activated macrophages during inflammation, playing pathological roles as one of damage-associated molecular patterns (DAMPs) (Scaffidi et al., 2002; Harris and Raucci, 2006; Klune et al., 2008; Sims et al., 2010) . HMGB1, once released into the extracellular space, is capable of binding to multiple cell surface receptors such as receptors for advanced glycation end products (RAGE) and toll-like receptor-4 (TLR4), facilitating inflammation and tissue damage (Wang et al., 1999; Schmidt et al., 2001; Scaffidi et al., 2002; Fiuza et al., 2003; Sunden-Cullberg et al., 2006) . Accumulating evidence suggests the role of HMGB1 in pain processing. HMGB1 in the spinal cord and/or dorsal root ganglion (DRG) is upregulated in surgical neuropathic pain models induced by L5 spinal nerve ligation (Shibasaki et al., 2010) or by chronic constriction injury of the sciatic nerve (Kuang et al., 2012) and in a diabetic neuropathic pain model (Ren et al., 2012) . Intrathecal administration of the neutralizing antibody against HMGB1 prevents or reverses the neuropathic pain/allodynia (Shibasaki et al., 2010; Ren et al., 2012) and bone cancer pain (Tong et al., 2010) . Acute direct application of HMGB1 causes hyperexcitability of dissociated nociceptive DRG neurons isolated from rats (Feldman et al., 2012) and hypersensitivity of sciatic nerves to mechanical stimuli in rats (Chacur et al., 2001) .
Interestingly, thrombomodulin (TM), an endothelial anticoagulant cofactor (Esmon, 2005) , binds to HMGB1 and promotes its degradation by thrombin, leading to suppression of inflammation (Abeyama et al., 2005; Ito et al., 2008; Ito and Maruyama, 2011) . TM is composed of five domains: the N-terminal lectin-like domain [thrombomodulin domain (TM-D) 1], epidermal growth factor (EGF)-like domain (TM-D2), O-glycosylation-rich domain (TM-D3), C-terminal trans-membrane domain (TM-D4) and cytoplasmic domain (TM-D5). TM-D2 plays a critical role in the thrombin-catalyzed activation of protein C to activated protein C (APC), while TM-D1 binds to HMGB1 (Abeyama et al., 2005) .
Recombinant human soluble TM (rhsTM) that lacks TM-D4 and TM-D5 is approved for clinical treatment of disseminated intravascular coagulation (DIC) in Japan (Ito et al., 2011) .
Although rhsTM appears to exhibit anti-inflammatory activity in a manner dependent on TM-D1 and TM-D2 in humans, rhsTM is incapable of causing TM-D2-dependent production of protein C in mammals including rodents other than primates (Mohri et al., 1997) .
Nonetheless, rhsTM exhibits anti-inflammatory activity through TM-D1-dependent sequestration of HMGB1 (Abeyama et al., 2005) and promotion of its degradation in rodents (Ito et al., 2008; Ito et al., 2011) . In this context, we hypothesize that rhsTM might modulate peripheral HMGM1-dependent facilitation of pain signals in rodents.
In the present study, we thus tested if peripheral local injection of HMGB1 causes hyperalgesia in rats, and evaluated the effect of systemic administration of rhsTM on the peripheral HMGB1-dependent hyperalgesia. Here we provide evidence for the pronociceptive roles of HMGB1 in the peripheral tissue and novel therapeutic usefulness of rhsTM in relieving various types of clinical pain.
Methods

Animals
Male Wistar rats (7-10 weeks old) were purchased from Kiwa Laboratory Animals Co., Ltd.
(Wakayama, Japan). All animals were used with approval by Kinki University School of All studies involving animals are reported in accordance with the ARRIV guidelines for reporting experiments involving animals McGrath et al., 2010) .
Drugs and administration schedules
Lipopolysaccharide (LPS) (Escherichia coli Serotype O26:B6) was purchased from Sigma-Aldrich Chemical (St Louis, MO). HMGB1 from bovine thymus, chicken anti-HMGB1 polyclonal antibody (neutralizing antibody) and chicken IgY were obtained from SHINO-TEST Corporation (Kanagawa, Japan). Recombinant human soluble thrombomodulin (rhsTM; thrombomodulin alfa) was provided by Asahi Kasei Pharma (Tokyo, Japan). LPS and HMGB1 were dissolved in saline, and rhsTM was in 0.002% Tween 80-containing saline. The neutralizing antibody and chicken IgY were dissolved in 0.2 M PBS.
Rats received intraplantar (i.pl.) administration of HMGB1 at 2, 10 or 20 μg per paw or LPS at 1 μg per paw in a volume of 0.1 ml. The HMGB1-neutralizing antibody or chicken IgY at 50 or 100 μg per paw was coadministered i.pl. with LPS at 1 μg per paw in a volume of 0.1 ml. rhsTM in a dose range of 0.001-10 mg kg -1 was administered i.p. to rats 30 min before i.pl.
administration of HMGB1 or LPS, considering the previous reports (Abeyama et al., 2005; Shi et al., 2008) .
Measurement of mechanical and thermal nociception and of paw thickness
Mechanical nociception was evaluated by the paw pressure test, using an analgesia meter (MK-300, Muromachi Kikai Co., Tokyo, Japan); pressure was applied to the hindpaw of rats at a linearly increasing rate of 30 g s -1 . The weight required to elicit nociceptive responses was determined as the nociceptive threshold, and a cut-off value of 500 g was used to avoid damage to the paw (Kawabata et al., 2007) . In some experiments, the paw withdrawal latency to thermal stimuli was measured using a thermal analgesia meter (MK-330, Muromachi Kikai), as reported previously (Kawabata et al., 2001) . The intensity of the thermal stimulus 
Determination of HMGB1 protein levels in the serum, hindpaw plantar tissue and DRG from rats
Under anesthesia with i.p. administration of urethane at 1.5 g kg -1 , the blood was collected from the abdominal aorta in the rats 1 h or 5 h after i.pl. LPS, and the ipsilateral DRG at L4-L6 levels and hindpaw plantar tissues (up to a level of the heel bone and metatarsal bones)
were excised from the rats. Serum HMGB1 levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit for HMGB1 (SHINO-TEST Corporation, Kanagawa, Japan 
Determination of mRNA levels of HMGB1, RAGE and TLR4 in the hindpaw plantar tissue and DRG from rats
The excised tissues were stabilized in an RNAlater reagent (Ambion, Austin, TX, USA). Total RNA was extracted from the homogenate of the bladder in the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). After the total RNA was reverse-transcribed, real-time PCR was performed using Light Cycler 480 (Roche Applied Sci., Basel, Switzerland). The volume of each reaction solution was 20 l, containing 10 l of 2× Power SYBR Green PCR Master
Mix (Applied Biosystems Japan Ltd., Tokyo, Japan), 100 ng cDNA and 0.2 M each of forward and reverse primers. The cycling conditions of PCR were: preincubation at 50°C for 9 2 min followed by 95°C for 10 min, then 45 cycles of 95°C for15 s and 60°C for 60 s. The PCR primers employed for real-time PCR were: 5'-GTAATTTTCCGCGCTTTTGT-3' (forward) and 5'-TCATCCAGGACTCATGTTCAGT-3' (reverse) for rat HMGB1;
5'-ACTACCGAGTCCGAGTCTACC-3' (forward) and 5'-GTAGCTCCCCTCAGACACACA-3' (reverse) for rat RAGE;
5'-CGGAAAGTTATTGTGGTGGTG-3' (forward) and 5'-GGACAATGAAGATGATGCCAG-3' (reverse) for rat TLR4;
5'-GATGGTGAAGGTCGGTGTGAAC-3' (forward) and 5'-TGACTGTGCCGTTGAACTTGC-3' (reverse) for rat GAPDH. The product size was 114, 116, 121, and 176 bp for HMGB1, RAGE, TLR4, and GAPDH, respectively. It is to be noted that TLR4 is defined in accordance with the nomenclature of the Guide to Receptors and Channels (Alexander et al., 2011) .
Morphological observation of the rat hindpaw tissue
In some experiments, the hindpaw plantar tissue was fixed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for morphological observation.
Statistics
Data are represented as means ± SEM. Statistical analyses were performed by Student's t-test for two-group data and by Tukey's test for multiple comparisons. Differences among experimental groups were considered significant when P < 0.05.
Results
Hyperalgesia induced by i.pl. administration of HMGB1 and its prevention by systemic administration of rhsTM in rats
HMGB1, administered i.pl. at 10 and 20 μg per paw, but not 2 μg per paw, into the left hindpaw, gradually decreased the mechanical nociceptive threshold ( Figure 1A ). The paw thickness, an indicator of oedema, significantly increased and reached a plateau 1 h after i.pl. Figure 1E ). On the other hand, rhsTM at relatively higher doses, 0.1-1 mg kg -1 , reduced the HMGB1-induced paw swelling ( Figure 1F ). rhsTM at 10 mg kg -1 altered neither mechanical nociceptive threshold nor paw thickness in naïve rats (n = 4-5, P > 0.05; not shown).
The HMGB1-neutralizing antibody inhibits the hyperalgesia induced by i.pl. LPS in rats
To clarify the role of endogenous HMGB1 in the development of inflammatory pain, we used a rat model for inflammatory hyperalgesia caused by LPS, known to trigger release of HMGB1 (Yanai et al., 2012) . LPS, administered i.pl. at 1 μg per paw, caused some histological signs of mild inflammation characterized by slight oedema and polynuclear leukocyte infiltration (Figure 2A ). The paw thickness, an indicator of oedema, rapidly increased within 2 h after i.pl. LPS ( Figure 2C ), whereas the mechanical nociceptive threshold gradulally decreased, reaching a plateau around 4-5 h after i.pl. LPS ( Figure 2B ), in agreement with our previous study (Kawabata et al., 2007) . Shortening of the paw withdrawal latency in response to thermal stimuli was also observed 5 h after i.pl. LPS ( Figure 2D ). The chicken anti-HMGB1 polyclonal antibody, a HMGB1-neutralizing antibody, when co-administered i.pl. at 50 and 100, but not 5, μg per paw with LPS, clearly prevented the development of the LPS-induced mechanical hyperalgesia ( Figure 2B ). The HMGB1-neutralizing antibody at 50 μg per paw failed to reduce the LPS-induced paw swelling, whereas a larger dose, 100 μg per paw, of the antibody significantly attenuated the paw swelling ( Figure 2C ). It was also confirmed that the LPS-induced thermal hyperalgesia was blocked by the HMGB1-neutralizing antibody ( Figure 2D ).
Antihyperalgesic effect of rhsTM in rats treated with LPS
Systemic (i.p.) preadministration of rhsTM at 10 mg kg -1 , a relatively high dose, abolished the LPS-induced hyperalgesia ( Figure 3A ) and largely prevented the paw swelling in rats ( Figure   3B ). In contrast, as did the HMGB1-neutralizing antibody ( Figure 2B , C), rhsTM at 0.01-1 mg kg -1 , lower doses, almost completely inhibited the LPS-induced hyperalgesia, but not paw swelling ( Figure 3C, D) . Boiled rhsTM at 10 mg kg -1 unaffected the LPS-induced mechanical hyperalgesia ( Figure 3E ) or paw swelling ( Figure 3F ).
Protein levels of HMGB1 in the hindpaw plantar tissue, DRG and serum of the rats after i.pl. LPS
HMGB1 protein levels in the ipsilateral (left) hindpaw tissue significantly decreased 5 h, but not 1 h, after i.pl. administration of LPS in the left hindpaw ( Figure 4A , B). In DRG, HMGB1 levels did not change by LPS treatment ( Figure 4C ). Preadministration of rhsTM did not prevent the LPS-induced decrease in the hindpaw HMGB1 levels ( Figure 4B ). Serum HMGB1 levels tended to increase 5 h after i.pl. administration of LPS in the rats treated with vehicle, but not rhsTM at 10 mg kg -1 (Figure 4E ), while no change in serum HMGB1 levels was detected 1 h after i.pl. LPS ( Figure 4D ). rhsTM at 10 mg kg -1 itself did not affect HMGB1 levels in the hindpaw ( Figure 4F ), but significantly decreased serum HMGB1 levels ( Figure 4G ).
mRNA levels for HMGB1, RAGE and TLR4 in the hindpaw plantar tissue and DRG after i.pl.
LPS in the rats
There was no significant change in mRNA levels for HMGB1, RAGE and TLR4 in the hindpaw or DRG 5 h after i.pl. administration of LPS in rats ( Figure 5 ).
Discussion and conclusions
Our findings that a single i.pl. administration of HMGB1 caused mechanical and thermal hyperalgesia and that the HMGB1-neutralizing antibody abolished the LPS-induced hyperalgesia, suggest that peripheral HMGB1 plays a major role in nociceptor sensitization during inflammation. Further, our study demonstrates that rhsTM, known to sequester HMGB1 and promote its degradation, actually blocks the hyperalgesia caused by HMGB1 or LPS, implying novel therapeutic usefulness of rhsTM as an analgesic, in addition to a medicine for treatment of DIC.
HMGB1, a nuclear, non-histone DNA-binding protein, is expressed in extensive cells including neurons, and released actively or passively during inflammation (Kim et al., 2008; Klune et al., 2008) . There is evidence for involvement of exogenous and endogenous HMGB1 in pain processing (Chacur et al., 2001; Tong et al., 2010; Feldman et al., 2012) . In particular, HMGB1 present in the DRG and spinal cord appears to participate in the pathogenesis of neuropathic pain (Shibasaki et al., 2010; Kuang et al., 2012; Ren et al., 2012) .
Our present study provides novel evidence for involvement of exogenous and endogenous HMGB1 in the development of peripheral hyperalgesia. rhsTM sequesters HMGB1 (Abeyama et al., 2005) and thereafter accelerates proteolytic degradation of HMGB1 by thrombin that takes 1-2 h in vitro (Ito et al., 2008) . Therefore, our results that the development of paw swelling preceded the onset of hyperalgesia after i.pl. administration of HMGB1, might interpret why rhsTM exerted relatively minor inhibitory effect on the HMGB1-induced paw swelling, compared with its strong effect on the hyperalgesia (see Figure 1A , B).
HMGB1 is considered to greatly participate in the LPS-induced hyperalgesia, but moderately contribute to the paw swelling, considering the extent of the effects of the HMGB1-neutralizing antibody (see Figure 2 ). This is in agreement with our results that rhsTM at relatively low doses prevented the development of the LPS-induced hyperalgesia, but not paw swelling (see Figure 3C , D). It is noteworthy that slight oedema, in addition to polynuclear leukocyte infiltration, was observed in the hindpaw tissues following i.pl. LPS, but not HMGB1 (see Figures 1D and 2A) . The LPS-induced oedema or swelling in the hindpaw would thus appear to involve other pro-inflammatory mediators in addition to endogenous HMGB1. Nonetheless, rhsTM at 10 mg kg -1 , a high dose, abolished both LPS-induced hyperalgesia and paw swelling (see Figure 3A , B). This might be explained by the previous evidence that TM also sequesters LPS through the TM-D1 at relatively high concentrations (Shi et al., 2008) . The possibility cannot be ruled out that the different timing paradigm for administration of the anti-HMGB1 antibody and rhsTM that were coadministered and preadministered, respectively, might affect the extent of their inhibitory effects on the paw swelling.
Our data show that LPS treatment significantly and clearly decreased the protein levels of HMGB1 in the hindpaw plantar tissue, but not DRG, an effect resistant to rhsTM (see Figure   4 ). It is now known that pro-inflammatory stimuli including LPS challenge cause active and passive release of HMGB1 from various tissues/cells (Taniguchi et al., 2003; Oyama et al., 2010; Tsoyi et al., 2011; Nadatani et al., 2012; Wu et al., 2012) , which might result in the decreased tissue HMGB1 levels, as shown in the present study. Although systemic LPS is known to increase serum HMGB1 levels (Lamkanfi et al., 2010; Yanai et al., 2012) , i.pl.
administration of LPS only slightly increased serum HMGB1 levels in rats treated with vehicle, but not rhsTM, in the present study. It is likely that a small amount of HMGB1 released persistently from the hindpaw tissue in response to i.pl. administration of LPS might enter the blood stream and quickly disappear because of degradation by endothelial TM-thrombin complexes (Ito et al., 2008) . In future studies, it would be necessary to detect extracellular HMGB1 released locally from the cells using a perfusion system.
HMGB1 interacts with multiple cell surface receptors including RAGE and TLR4, a receptor for LPS (Wang et al., 1999; Schmidt et al., 2001; Scaffidi et al., 2002; Fiuza et al., 2003; Sunden-Cullberg et al., 2006) . RAGE is also expressed in neurons, modulates neuronal functions, and may be involved in diabetic neuropathy (Brett et al., 1993; Chou et al., 2004; Sugimoto et al., 2008) . Our finding that the HMGB1-neutralizing antibody completely blocked the LPS-induced hyperalgesia, but exerted only partial inhibition of paw swelling (see Figure 2B , C, D), may suggest that endogenous HMGB1 causes hyperalgesia via activation of RAGE or other receptors distinct from TLR4, although neither RAGE nor TLR4
was upregulated at mRNA levels (see Figure 5 ). What molecules HMGB1 targets for induction of hyperalgesia are still open to question. In the present study, the anti-HMGB1 neutralizing antibody was injected locally to the plantar region of the hindpaw, so that it would act locally within the paw tissues, considering the effective dose of the antibody that is not enough to be distributed at effective concentrations in the blood. However, the possibility cannot be ruled out that the anti-hyperalgesic effect of systemically administered rhsTM involves its actions on tissues/cells out of the paw tissue, including the brain and spinal cord, although rhsTM is not considered to easily penetrate into the CNS in consideration of its large molecular size.
In conclusion, our data suggest that peripheral HMGB1 plays important roles in the development of inflammatory hyperalgesia and that rhsTM is available as a novel analgesic for treatment of HMGB1-mediated inflammatory pain/hyperalgesia.
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